CellOxess to Showcase Fertilix® at the American Society of Reproductive Medicine 2015 Annual Meeting
From October 19th-21st, representatives from CellOxess will be showcasing Fertilix® at the American Society of Reproductive Medicine (ASRM) Annual Meeting, as well as presenting original research sponsored by the company. ASRM is the largest society for reproductive health, andrology, endocrinology, obstetrics, and gynecology in the United States, whose mission is “Steering reproductive medicine to the forefront of global public health.” The meeting includes presentations of the latest research, exhibitions, opportunities for networking, and educational programs for professionals. Over 8000 physicians and other professionals attend the meeting each year.
ASRM 2015 will be held at the Baltimore Convention Center, 1 W Pratt Street, Baltimore, MD, and representatives from CellOxess will be available for inquiries at Booth #624 for the duration of the conference. We are currently seeking clinical collaborators for sponsored research initiatives and clinical trial support.
The conference schedule can be found on the ASRM 2015 website, and the abstracts for CellOxess’ scientific presentations will be available on the company website soon. The first poster being presented, entitled “Cytotoxic effects of membrane lipid peroxidation products on human spermatozoa” (P-117) details findings from a series of experiments by CellOxess scientists and our collaborations at the Aitken lab at the University of Newcastle in Newcastle, Australia. This study, now published as “Editor’s Choice” in Molecular Human Reproduction, takes a close look at the products of sperm membrane lipid peroxidation and their effects of cell heath. The authors found that, contrary to common belief, not all lipid aldehydes are equally cytotoxic. In fact, several molecules commonly used as biomarkers of lipid peroxidation and oxidative stress had no cytotoxic effects on sperm under the conditions studies. Such differing reactivity between molecules could influence choices of biomarkers in future research. The second poster, “A novel antioxidant formulation designed to treat male infertility associated with oxidative stress: promising preclinical evidence from mouse models” (P-123) discusses the ingredient selection criteria and positive preclinical results of Fertilix®, CellOxess’ flagship product. Utilizing two different rodent models, independent laboratories showed that Fertilix® was able to prevent the deleterious effects of oxidative stress on sperm health. CellOxess scientists will be presenting these works on Tuesday, October 20th from 7:00am-8:45am.
For more information, interested parties are encouraged to stop by Booth #624 during the conference. To schedule an individual meeting with a scientific or marketing representative, please contact Todd West at email@example.com.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.